Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AC Immune is a clinical-stage Swiss biopharmaceutical company focused on precision medicine for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. The company's proprietary platforms target misfolded proteins (tau, alpha-synuclein, amyloid-beta) and operates through strategic partnerships with Janssen, Genentech, and Eli Lilly, generating milestone payments and research funding while advancing its wholly-owned pipeline including ACI-35.030 (tau vaccine) and ACI-7104 (anti-tau antibody).
AC Immune operates a capital-efficient partnered model where it out-licenses proprietary antibody and vaccine platforms to large pharma partners in exchange for upfront payments, research funding, development milestones (potentially $50-200M per program), and royalties on future sales. The company retains certain geographic rights and advances wholly-owned assets to inflection points before seeking partnerships. With negative gross margins reflecting R&D-stage operations, value creation depends on clinical trial success triggering milestone payments and eventual royalty streams from commercialized products, with peak sales potential exceeding $1B for successful Alzheimer's therapies.
Clinical trial data readouts for ACI-35.030 Phase 2 tau vaccine and ACI-7104 anti-tau antibody programs
Partnership announcements, milestone achievements, or expansions with Janssen, Genentech, or new pharma collaborators
Competitive Alzheimer's drug approvals or failures (Eli Lilly's donanemab, Eisai's lecanemab) affecting sector sentiment
FDA regulatory pathway clarity for tau-targeting therapies and biomarker-driven trial designs
Cash runway updates and financing activities given $0.3B market cap and ongoing burn rate
High clinical trial failure risk inherent to neurodegenerative diseases with 90%+ historical Phase 2/3 failure rates for Alzheimer's programs, particularly for tau-targeting mechanisms with limited prior validation
Regulatory pathway uncertainty as FDA evolves standards for accelerated approval based on biomarkers versus clinical endpoints following controversial aducanumab approval and subsequent market withdrawal
Partnership dependency risk where 70-80% of revenue derives from three pharma collaborators who control development decisions and can terminate programs
Intense competition from better-capitalized players (Eli Lilly, Eisai/Biogen, Roche) with anti-amyloid therapies gaining traction, potentially reducing pharma interest in alternative tau-targeting mechanisms
Risk that successful amyloid-targeting drugs (lecanemab, donanemab) capture Alzheimer's market before tau therapies demonstrate superiority, limiting commercial opportunity
Cash runway risk with current ratio of 1.16 and negative operating margins requiring periodic equity raises that dilute existing shareholders, particularly challenging in adverse biotech funding environments
Concentration risk with limited revenue diversification beyond three major partnerships, creating binary dependence on partner decisions and milestone achievement
low - Pre-revenue biotech with revenue driven by partnership milestones and clinical progress rather than economic activity. However, severe recessions can impact pharma partners' R&D budgets and willingness to fund external collaborations, potentially delaying milestone payments or new partnership formations.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (royalties potentially 5-10+ years out) and increase financing costs for future capital raises. Clinical-stage biotechs with no near-term profitability are particularly sensitive to rate-driven multiple compression. Lower rates support higher risk appetite for speculative growth assets and improve access to capital markets.
Minimal direct credit exposure. Company relies on equity markets and partnership payments rather than debt financing (Debt/Equity 0.07). However, tightening credit conditions reduce biotech sector liquidity and increase dilution risk if forced to raise capital during unfavorable market windows.
growth - Attracts speculative biotech investors seeking asymmetric upside from clinical trial success and eventual royalty streams. High-risk/high-reward profile appeals to sector specialists willing to underwrite binary clinical outcomes and multi-year development timelines. Not suitable for income or value investors given no profitability, dividends, or tangible book value.
high - Clinical-stage biotech with binary catalysts (trial data, partnership news) creating 20-40%+ single-day moves. Small market cap ($0.3B) amplifies volatility from modest trading volume. Historical beta likely exceeds 1.5x relative to broader market given sector and development stage risk.